Innate Pharma (PK) Stock Quote IPHYF - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.9301

Bid

1.94

Ask

2.77

Volume

0.00 Day's Range 0.00

1.9301 52 Week Range 3.00

Market Cap

614.101M

Previous Close

1.9301

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

2,614

Shares Outstanding

318,170,508

Dividend Yield

PE Ratio

-87.82

Earnings Per Share (EPS)

-0.02

Revenue

61.64M

Net Profit

-7.57M

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on... Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.innate-pharma.com

Headquarters

Marseille, Bouches-du-rhone, Fra

Founded

1970

Innate Pharma (PK) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker IPHYF. The last closing price for Innate Pharma (PK) was $1.93. Over the last year, Innate Pharma (PK) shares have traded in a share price range of $ 1.9301 to $ 3.00.

Innate Pharma (PK) currently has 318,170,508 shares outstanding. The market capitalization of Innate Pharma (PK) is $614.10 million. Innate Pharma (PK) has a price to earnings ratio (PE ratio) of -87.82.

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	1.9301	1.9301	1.9301	500	1.9301	CS
12	-0.1999	-9.38497652582	2.13	2.77	1.9301	2614	2.32754372	CS
26	-0.5899	-23.4087301587	2.52	2.77	1.9301	1538	2.3454325	CS
52	-1.0599	-35.4481605351	2.99	3	1.9301	930	2.43074491	CS
156	-1.2199	-38.726984127	3.15	11	1.93	1702	4.70829817	CS
260	-5.0199	-72.2287769784	6.95	11	1.93	1607	5.09595089	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
POAIPredictive Oncology Inc	$ 2.5094 (134.52%)	115.59M
PBMPsyence Biomedical Ltd	$ 0.73 (86.51%)	57.25M
SLRXSalarius Pharmaceuticals Inc	$ 3.275 (53.04%)	12.92M
VKTXViking Therapeutics Inc	$ 66.02 (30.97%)	7.23M
GSHDGoosehead Insurance Inc	$ 84.79 (29.06%)	322.28k
TWOU2U Inc	$ 1.59 (-61.41%)	2.05M
EZFLEzFill Holdings Inc	$ 3.86 (-37.99%)	50.01k
KDLYKindly MD Inc	$ 2.07 (-35.71%)	427.26k
MXLMaxLinear Inc	$ 16.0199 (-28.13%)	1.85M
GLYCGlycoMimetics Inc	$ 0.2279 (-26.55%)	3.86M
NVDANVIDIA Corporation	$ 110.5146 (-3.27%)	153.92M
POAIPredictive Oncology Inc	$ 2.5094 (134.52%)	115.59M
SLNASelina Hospitality PLC	$ 0.0432 (-5.47%)	110.58M
SQQQProShares UltraPro Short QQQ	$ 9.29 (2.54%)	78.76M
STSSSharps Technology Inc	$ 0.268 (12.94%)	57.48M